Virology
Jake Scott put the ID in COVID-19
By Vincent Racaniello
Infectious Disease physician Jake Scott joins TWiV to provide a west coast clinical perspective on the evolution of the COVID-19 pandemic with respect to the impact of vaccines, antivirals, variants of concern and mortality. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Kathy Spindler Guest: Jake Scott Click arrow to playDownload TWiV ...
TWiV 951: Clinical update with Dr. Daniel Griffin
By Vincent Racaniello
In his weekly clinical update Dr. Griffin discusses Influenza incidence and vaccine effectiveness during the southern hemisphere influenza season in Chile, Nirsevimab for prevention of RSV infection in healthy late-preterm and term infants, severe Monkeypox in hospitalized patients, reinfections with different SARS-CoV-2 Omicron subvariants, impact of community masking on COVID-19 in Bangladesh, unadjuvanted ...
Antibodies Against SARS-CoV-2 Nucleocapsid Protein May Not Be Reliable Markers for Infection in Vaccinated People
By Gertrud U. Rey
by Gertrud U. Rey You are fully vaccinated against SARS-CoV-2 and have presumably never been infected with the virus. But how can you know for sure? One way to find out is by testing your blood for the presence of antibodies against the viral nucleocapsid protein, which can only be ...
TWiV 950: Prion diseases with Richard Knight
By Vincent Racaniello
From the European Society for Clinical Virology 2022 Conference in Manchester UK, Vincent speaks with Richard Knight about prion diseases and the outbreak of bovine spongiform encephalitis that led to cases of variant Creutzfeldt-Jakob disease in humans. Host: Vincent Racaniello Guest: Richard Knight Click arrow to playDownload TWiV 950 (68 MB .mp3, 114 ...
TWiV 949: Clinical update with Dr. Daniel Griffin
By Vincent Racaniello
In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18–50 years and RSV seropositive ...